Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin

Prostate

Volumn 48, Issue 1, 2001, Pages 7-15

  Xing, Nianzeng ^a,b   Qian, Junqi ^c   Bostwick, David ^c   Bergstralh, Erik ^a   Young, Charles Y F ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c BOSTWICK LABORATORIES   (United States)

Author keywords

Adenocarcinoma; Apoptosis; Chromogranin A; Neuroendocrine; Prostate; Survivin

Indexed keywords

CHROMOGRANIN A; PROTEIN BCL 2; SURVIVIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROSECRETORY CELL; NICK END LABELING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; APOPTOSIS; CHI-SQUARE DISTRIBUTION; CHROMOGRANIN A; CHROMOGRANINS; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MORPHOGENESIS; NEOPLASM PROTEINS; NEUROSECRETORY SYSTEMS; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEINS; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035876175     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1076     Document Type: Article

References (47)

1. Neuroendocrine differentiation in human prostatic carcinoma
2. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives
3. Neuroendocrine differentiation in prostatic malignancy
4. Receptors for BPH growth factors are located in some neuroendocrine cells
5. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma
6. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate
7. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker"
8. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy
9. Elevated plasma chromogranin-A concentrations in prostatic carcinoma
10. Prostatic adenocarcinoma evolving into carcinoid: Selective effect of hormonal treatment?
11. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate
12. Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma
13. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment
14. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation
15. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?
16. Serum chromogranin A. early detection of hormonal resistance in prostate cancer patients
17. Apoptosis in the pathogenesis and treatment of disease
18. Prognostic significance of Bcl-2 in clinically localized prostate cancer
19. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
20. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
21. Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: Cell kinetic features of neuroendocrine cells in the human prostate
22. BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell
23. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts
24. Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and cytochrome c
25. X-linked IAP is a direct inhibitor of cell-death proteases
26. A single BIR domain of XIAP sufficient for inhibiting caspases
27. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
28. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer
29. Developmentally regulated expression of the novel cancer antiapoptosis gene survivin in human and mouse differentiation
30. Prognostic significance of survivin expression in diffuse large B-cell lymphomas
31. Cancer statistics, 1999
32. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy
33. Prognostic significance of neuroendocrine differentiation in carcinoma of the prostate
34. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy
35. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma
36. Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer
37. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy
38. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma
39. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?
40. Communication: Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin
41. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma
42. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas
43. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
44. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer
45. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma
46. Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MIB-1), and phenotype markers in routinely processed tissue sections
47. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting